Skip to main content

Search Videos and More

Showing 61 - 70 of 70 results

Previous| 1... 4 | 5 | 6 |Next

As an interventional cardiologist in the UK, what do the results from the ODYSSEY Outcomes Trial and price reductions mean to the clinician at the front lines of cardiology care as far as access to and triggers for deploying a PCSK9 inhibitor?

As an interventional cardiologist in the UK, what do the results from the ODYSSEY Outcomes Trial and price reductions mean to the clinician at the front lines of cardiology care as far as access to and triggers for deploying a PCSK9 inhibitor?

What other markers, besides LDL-C levels, do you believe we should consider to refine CV risk stratification?

What other markers, besides LDL-C levels, do you believe we should consider to refine CV risk stratification?

Considering that younger persons are vulnerable to carrying a lifelong atherosclerosis burden when their LDL-C levels are elevated, how to do approach them management-wise?

Considering that younger persons are vulnerable to carrying a lifelong atherosclerosis burden when their LDL-C levels are elevated, how to do approach them management-wise?

Representing the landscapes of IC and atherosclerosis prevention/lipid management, How do you identify “progressing patients” with high CV risk in whom PCSK9 therapy represents a game-changing strategy?

Representing the landscapes of IC and atherosclerosis prevention/lipid management, How do you identify “progressing patients” with high CV risk in whom PCSK9 therapy represents a game-changing strategy?

From the view of an interventional cardiologist and a lipid medicine/atherosclerosis specialist, can you discuss what LDL-C thresholds vs. clinical burden/clinical history thresholds are important for patient selection for PCSK9-based risk reduction?

From the view of an interventional cardiologist and a lipid medicine/atherosclerosis specialist, can you discuss what LDL-C thresholds vs. clinical burden/clinical history thresholds are important for patient selection for PCSK9-based risk reduction?

In light of the effectiveness and safety in post-ACS patients of the “ultra-low” levels of LDL-C achieved in the ODYSSEY Outcomes and FOURIER Trials, how has that shaped your clinical perspective on the role of PCSK9 inhibitors in high-risk patients?

In light of the effectiveness and safety in post-ACS patients of the “ultra-low” levels of LDL-C achieved in the ODYSSEY Outcomes and FOURIER Trials, how has that shaped your clinical perspective on the role of PCSK9 inhibitors in high-risk patients?

You have introduced the concept of progressive atherosclerotic burden to characterize the multiplicity of biologic, metabolic & clinical markers in a CV risk profile. How do you apply this “aggregated risk” to patient selection for PCSK9 inhibitors?

Do you use different LDL-C levels in persons with diabetes to justify initiation of PCSK9 inhibitors? Is the presence of ACS required or symptomatic ASCVD required to triage them into PCSK9-based treatment?

Do you use different LDL-C levels in persons with diabetes to justify initiation of PCSK9 inhibitors? Is the presence of ACS required or symptomatic ASCVD required to triage them into PCSK9-based treatment?

In your mind, as a Director of a Lipid Clinic and Preventive Cardiology Center, how do you apply the results of the ODYSSEY Outcomes and other trials in terms of the lack of safety signals when lowering LDL-C to levels < 50 mg/dL?

In your mind, as a Director of a Lipid Clinic and Preventive Cardiology Center, how do you apply the results of the ODYSSEY Outcomes and other trials in terms of the lack of safety signals when lowering LDL-C to levels < 50 mg/dL?

What are the specific patient types that you manage in your lipid-focused practice and which are referred to you for potential intervention with a PCSK9 inhibitor? Why are these patients being referred to you for PCSK9-mediated LDL-C reduction?

What are the specific patient types that you manage in your lipid-focused practice and which are referred to you for potential intervention with a PCSK9 inhibitor? Why are these patients being referred to you for PCSK9-mediated LDL-C reduction?

Showing 61 - 70 of 70 results

Previous| 1... 4 | 5 | 6 |Next